CY1123137T1 - Ιμιδαζο[1.2α]πυριδινες για αντιμετωπιση ή προληψη υπερουριχαιμιας ή ουρικης αρθριτιδας - Google Patents

Ιμιδαζο[1.2α]πυριδινες για αντιμετωπιση ή προληψη υπερουριχαιμιας ή ουρικης αρθριτιδας

Info

Publication number
CY1123137T1
CY1123137T1 CY20201100660T CY201100660T CY1123137T1 CY 1123137 T1 CY1123137 T1 CY 1123137T1 CY 20201100660 T CY20201100660 T CY 20201100660T CY 201100660 T CY201100660 T CY 201100660T CY 1123137 T1 CY1123137 T1 CY 1123137T1
Authority
CY
Cyprus
Prior art keywords
prevention
treatment
hyperurachemia
pyridines
imidazo
Prior art date
Application number
CY20201100660T
Other languages
English (en)
Inventor
Dongfang Shi
Changjin FU
Xi CHENG
Jianghua Zhu
Jie Wen
Jie Gu
Original Assignee
Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd filed Critical Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd
Publication of CY1123137T1 publication Critical patent/CY1123137T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents

Abstract

Παρέχονται μία ένωση όπως παριστάνεται στον Τύπο (Ι), φαρμακευτικώς αποδεκτά άλατα αυτής,φαρμακευτικές συνθέσεις αυτής, και χρήσεις αυτής. Η ένωση όπως παριστάνεται στον Τύπο (Ι) και τα φαρμακευτικώς αποδεκτά άλατα αυτής χρησιμοποιούνται στην παρασκευή φαρμάκων για τηναντιμετώπιση ή πρόληψη υπέρουριχαιμίας ή ουρικής αρθρίτιδας μέσω της απέκκρισης ουρικού οξέος.
CY20201100660T 2015-09-10 2020-07-17 Ιμιδαζο[1.2α]πυριδινες για αντιμετωπιση ή προληψη υπερουριχαιμιας ή ουρικης αρθριτιδας CY1123137T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201510576110 2015-09-10
PCT/CN2016/098468 WO2017041732A1 (zh) 2015-09-10 2016-09-08 一类用于治疗或预防高尿酸血症或痛风的化合物

Publications (1)

Publication Number Publication Date
CY1123137T1 true CY1123137T1 (el) 2021-10-29

Family

ID=58164535

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20201100660T CY1123137T1 (el) 2015-09-10 2020-07-17 Ιμιδαζο[1.2α]πυριδινες για αντιμετωπιση ή προληψη υπερουριχαιμιας ή ουρικης αρθριτιδας

Country Status (26)

Country Link
US (1) US10399971B2 (el)
EP (1) EP3348557B1 (el)
JP (1) JP6635527B2 (el)
KR (1) KR102109061B1 (el)
CN (1) CN106432229B (el)
AU (1) AU2016320073B2 (el)
BR (1) BR112018004863B1 (el)
CA (1) CA2998034C (el)
CY (1) CY1123137T1 (el)
DK (1) DK3348557T3 (el)
EA (1) EA037280B1 (el)
ES (1) ES2803223T3 (el)
HR (1) HRP20201094T1 (el)
HU (1) HUE051448T2 (el)
IL (1) IL257960A (el)
LT (1) LT3348557T (el)
MX (1) MX2018003006A (el)
MY (1) MY195675A (el)
NZ (1) NZ741318A (el)
PL (1) PL3348557T3 (el)
PT (1) PT3348557T (el)
RS (1) RS60697B1 (el)
SG (1) SG11201802010QA (el)
SI (1) SI3348557T1 (el)
TW (1) TWI681772B (el)
WO (1) WO2017041732A1 (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018090921A1 (zh) * 2016-11-16 2018-05-24 江苏新元素医药科技有限公司 Urat1抑制剂及其应用
WO2018214961A1 (zh) * 2017-05-26 2018-11-29 江苏新元素医药科技有限公司 促尿酸排泄的urat1抑制剂
CN114213331A (zh) * 2017-05-26 2022-03-22 江苏新元素医药科技有限公司 一类urat1抑制剂及其应用
JP7266901B2 (ja) * 2018-01-19 2023-05-01 エボポイント、バイオサイエンシズ、カンパニー、リミテッド 複素環式化合物、調製方法及びその医薬的な応用
CN111410654B (zh) * 2019-01-19 2022-05-17 江苏新元素医药科技有限公司 3-溴-5-(2-乙基咪唑并[1,2-a]吡啶-3-羰基)-2-羟基苯甲腈的合成
CN111943957B (zh) * 2019-05-17 2023-01-06 中国医学科学院药物研究所 喹啉甲酰胺类化合物及其制备方法和用途
WO2022169974A1 (en) * 2021-02-05 2022-08-11 Nexys Therapeutics, Inc. Inhibitors of urat1 and pharmaceutical uses thereof
TW202342456A (zh) * 2022-04-27 2023-11-01 大陸商江蘇新元素醫藥科技有限公司 可用於降尿酸的化合物
WO2023221078A1 (en) * 2022-05-20 2023-11-23 Jiangsu Atom Bioscience And Pharmaceutical Co., Ltd. Solid forms of a compound for treating or preventing hyperuricemia or gout

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ193926A (en) * 1979-07-06 1984-05-31 Labaz Sanofi Nv 2-(alkyl or phenyl)-3(4-hydroxybenzoyl)indolizines
FR2647451B1 (fr) * 1989-05-26 1994-08-05 Sanofi Sa Derives d'imidazo(1,2-a)pyridine, procede de preparation, compositions pharmaceutiques les contenant
JP5325065B2 (ja) * 2009-09-30 2013-10-23 株式会社富士薬品 新規フェノール誘導体
US10005750B2 (en) * 2010-10-06 2018-06-26 J-Pharma Co., Ltd. Developing potent urate transporter inhibitors: compounds designed for their uricosuric action
CA2880178C (en) * 2012-07-27 2021-10-26 Sato Pharmaceutical Co., Ltd. Difluoromethylene compound

Also Published As

Publication number Publication date
NZ741318A (en) 2019-03-29
EA201890694A1 (ru) 2018-10-31
SI3348557T1 (sl) 2020-09-30
TW201808284A (zh) 2018-03-16
CN106432229A (zh) 2017-02-22
BR112018004863A2 (el) 2018-10-02
US20180282321A1 (en) 2018-10-04
PL3348557T3 (pl) 2020-11-16
HRP20201094T1 (hr) 2020-10-30
KR102109061B1 (ko) 2020-05-11
CA2998034A1 (en) 2017-03-16
CA2998034C (en) 2021-05-04
TWI681772B (zh) 2020-01-11
PT3348557T (pt) 2020-08-03
IL257960A (en) 2018-05-31
RS60697B1 (sr) 2020-09-30
JP6635527B2 (ja) 2020-01-29
JP2018526417A (ja) 2018-09-13
HUE051448T2 (hu) 2021-03-01
KR20180044426A (ko) 2018-05-02
EP3348557A4 (en) 2019-03-06
LT3348557T (lt) 2020-08-10
MY195675A (en) 2023-02-03
AU2016320073A1 (en) 2018-04-26
EA037280B1 (ru) 2021-03-03
SG11201802010QA (en) 2018-04-27
MX2018003006A (es) 2018-08-09
EP3348557A1 (en) 2018-07-18
EP3348557B1 (en) 2020-04-29
AU2016320073B2 (en) 2019-05-09
DK3348557T3 (da) 2020-07-20
BR112018004863B1 (pt) 2023-04-18
US10399971B2 (en) 2019-09-03
WO2017041732A1 (zh) 2017-03-16
ES2803223T3 (es) 2021-01-25
CN106432229B (zh) 2018-01-12

Similar Documents

Publication Publication Date Title
CY1123137T1 (el) Ιμιδαζο[1.2α]πυριδινες για αντιμετωπιση ή προληψη υπερουριχαιμιας ή ουρικης αρθριτιδας
CY1123627T1 (el) Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου
CY1120031T1 (el) Αποπτωτικοι υποκινητες ν-ακυλοσουλφοναμιδης
CY1122566T1 (el) Παραγωγο 6,7,8,9-tetpaϋδpo-3h-πυραζολo[4,3-f] ισοκινολινης χρησιμο στη θεραπευτικη αντιμετωπιση του καρκινου
CY1124726T1 (el) Παραγωγα κιναζολινης που χρησιμοποιουνται για την αντιμετωπιση του hiv
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
CY1120248T1 (el) Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου
EP4071149A3 (en) Heterocyclic compounds and uses thereof
MX2018002402A (es) Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4).
BR112018071216A2 (pt) inibidores de bromodomínios
MY192521A (en) Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors
BR112017010354B8 (pt) Compostos de triazolopirimidina, seu uso, e composição farmacêutica
TN2018000395A1 (en) New (hetero)aryl-substituted-piperidinyl derivatives, a process for their preparation and pharmaceutical compositions containing them
MD3468974T2 (ro) Noi derivați de piperidinil, procedeu pentru prepararea lor și compoziții farmaceutice care ii conțin
TR201905009T4 (tr) Polisiklik-karbamoilpiridon bileşikleri ve bunların farmasötik kullanımları.
PH12018500061A1 (en) Oxysterols and methods of use thereof
BR112018007772A2 (pt) compostos de imidazo[4,5-c]quinolin-2-ona e seu uso no tratamento do câncer
BR112014018990A8 (pt) Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
BR112018007811A2 (pt) compostos de imidazo[4,5-c]quinolin-2-ona e seu uso no tratamento do câncer
MX2017008518A (es) Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
GEP20186938B (en) Indolizine derivatives as phoshoinositide 3-kinases inhibitors
TW201613864A (en) Novel compounds
MX2012008328A (es) Derivados de pirazina.
EA201600619A1 (ru) Хромен и 1,1а, 2,7в-тетрагидроциклопропа[с]хромен пиридопиразиндионы в качестве модулятора гамма-секретазы